Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
about
Ubiquitin-fold modifier 1 acts as a positive regulator of breast cancerIntegrative analysis of deep sequencing data identifies estrogen receptor early response genes and links ATAD3B to poor survival in breast cancerGenetically engineered mouse models of PI3K signaling in breast cancer.Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers.Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer.Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites.4-protein signature predicting tamoxifen treatment outcome in recurrent breast cancer.Effects of Pharmacogenetics on the Pharmacokinetics and Pharmacodynamics of Tamoxifen.Nodes-and-connections RNAi knockdown screening: identification of a signaling molecule network involved in fulvestrant action and breast cancer prognosis.Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patientsActivation of Akt, mTOR, and the estrogen receptor as a signature to predict tamoxifen treatment benefit.Mechanisms of resistance to endocrine therapy in breast cancer: focus on signaling pathways, miRNAs and genetically based resistance.Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer.An individualized prognostic signature for gastric cancer patients treated with 5-Fluorouracil-based chemotherapy and distinct multi-omics characteristics of prognostic groups.Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinomamiRNA clusters as therapeutic targets for hormone-resistant breast cancer.Estrogen receptor β isoform 5 confers sensitivity of breast cancer cell lines to chemotherapeutic agent-induced apoptosis through interaction with Bcl2L12.PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsPhosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment.Drug resistance to targeted therapies: déjà vu all over againNeoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies.Multi-omics landscapes of colorectal cancer subtypes discriminated by an individualized prognostic signature for 5-fluorouracil-based chemotherapy.Loss of protein tyrosine phosphatase, non-receptor type 2 is associated with activation of AKT and tamoxifen resistance in breast cancer.Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen.Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer.Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer.Oncoprotein HBXIP enhances HOXB13 acetylation and co-activates HOXB13 to confer tamoxifen resistance in breast cancer.Platform comparisons for identification of breast cancers with a BRCA-like copy number profile.OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.The role of the pathology department in the preanalytical phase of molecular analyses.Tumor-associated macrophages are correlated with tamoxifen resistance in the postmenopausal breast cancer patients.FOXA1 levels are decreased in pleural breast cancer metastases after adjuvant endocrine therapy, and this is associated with poor outcome
P2860
Q27016134-759674C0-B485-4AF0-8D79-6760D14A4397Q30652671-5EFA7D83-1692-40CD-8791-99CA64B4B9BEQ34332175-23EDACAB-9617-41A4-A8B4-6C05FDD5632CQ34854816-F85DB898-9855-40E0-8DEC-475308870C36Q35000662-D80FA233-197E-41FC-B5AA-7175D7081754Q35076890-DB518D25-B022-4973-B287-91B3399365A3Q35749170-FBE583B3-1146-45B4-97CF-9A968E6482E7Q35884159-A0A0A337-7374-49BC-BB50-7618819570ABQ36245954-41E45F8E-33F5-4767-A3D5-C304348D9C9DQ36310554-4FC13AE7-246F-4539-B456-3250284D4995Q36514782-B98A8ECE-C05C-4029-B7EE-FA88576362E6Q36589865-BD032DDB-F3F8-4A1B-93B6-8F4B12CB2CDBQ36772047-D07D7FDF-6AAB-42CE-ABA6-AC9141DE337FQ36962398-61E04999-5809-4CA6-9DCD-E839C71ABD3CQ37151107-BAA22E5A-80E3-4AED-B140-CC6E764636E8Q37316805-AF6BC028-4F26-48F4-B360-93660E87EC44Q37382513-B5DA0570-B92B-46C5-9FE8-7F4497FAA56CQ37690039-9DDF4B50-9447-48A2-A052-5802DE7A508EQ37691173-728C410C-2AF7-4172-BAAC-D0EA039C73CCQ38218657-033ACD17-48CC-4EB2-9B3D-AE9E631176BDQ39375196-13A65FC4-3D01-4E88-A24E-30F9E09740C0Q39590420-61D1ADE3-4562-469C-8013-B513C59BF99BQ41550474-DC50E3E0-827A-4082-8B80-486F21EF8A35Q44850155-825FEF2E-1CD3-4833-97FE-47726B7B7173Q47412586-63EFE1A3-5C99-49DF-AA49-53A9B31DB270Q49544395-16156E53-87C1-49C8-ACE1-6E6432AE59F0Q50301832-0F81B885-5363-4753-912B-EEF96B0DB5FCQ50997123-EFB5A364-1090-4849-995D-4FAB5BE690BCQ51451128-CD186D6A-C090-4C49-A2EC-8D7B11A6CE44Q52562703-8653C9FD-26EA-4CBB-820E-B8E5349E21B8Q54384989-AAE5D49A-0191-49A5-8911-AB9E00D750FEQ58738574-16B5D0C3-55AE-466A-9C94-B78B4AD5136E
P2860
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
@en
type
label
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
@en
prefLabel
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
@en
P2860
P1476
Can predictive biomarkers in breast cancer guide adjuvant endocrine therapy?
@en
P2093
Karin Beelen
Sabine C Linn
P2860
P304
P356
10.1038/NRCLINONC.2012.121
P407
P577
2012-07-24T00:00:00Z